Repetitive stimulation, also known as repetitive transcranial magnetic stimulation (rTMS), is a non-invasive procedure used to relieve neurological symptoms, such as chronic pain or depression. It is a type of neuromodulation method that works by delivering magnetic pulses through a coil to specific regions in the brain. The patient’s brain is exposed to this pulse for a few minutes at a time. The frequency and intensity of the TMS can be customized depending on the symptoms and the patient’s condition. The goal of rTMS is to improve the function of the affected areas of the brain. The exact mechanism by which rTMS works is not yet known, but researchers believe that the magnetic pulses interact with the neurons in the brain and spark a chain reaction of activity, resulting in the desired changes in the patient’s mental or physical health. Various studies suggest that repetitive stimulation may be beneficial for conditions such as stroke, memory deficits, Parkinson’s disease, and even autistic spectrum disorder. For example, a study conducted by researchers at Harvard Medical School found that the TMS treatment helped improve the motor skills of stroke patients. Other studies have also shown that rTMS may help improve cognitive functions in patients with Alzheimer’s disease. While research is still ongoing, these initial studies suggest that repetitive stimulation may be a promising new method of treating neurological disorders. However, as with any treatment, there are risks associated with repetitive stimulation. For instance, there is the potential for seizures, headaches, or other side effects. Therefore, it is important to work with an experienced physician to ensure that the treatment is tailored appropriately and used safely.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States